ArticleClinical case reports2026
Genetically Confirmed Osteogenesis Imperfecta (COL1A1) With Unexplained Ambiguous Genitalia in a 46,XY Child: An Index Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteogenesis imperfecta (OI) is a heritable disorder of type I collagen characterized by bone fragility, blue sclerae, and short stature. Disorders of sex development (DSD) in 46,XY individuals demand comprehensive endocrine, imaging, and genetic evaluation. We report a 6-year-old child with recurrent low-impact fractures, blue sclerae, short stature, and ambiguous genitalia. Karyotype was repeatedly reported as 46,XY. Subsequent endocrine evaluation revealed elevated follicle-stimulating hormone (16.03 mIU/mL), low luteinizing hormone (1.35 mIU/mL), markedly reduced testosterone (< 7 ng/dL), low dehydroepiandrosterone sulfate (< 15 μg/dL), and androstenedione (< 0.300 ng/mL), consistent with primary gonadal dysgenesis. Congenital adrenal hyperplasia was provisionally excluded. Whole-exome sequencing identified a heterozygous pathogenic frameshift variant in COL1A1 (c.441delC; p.Gly148fs*117), confirming OI, and a heterozygous CYP11A1 variant of uncertain significance (c.119 T > C; p.Ile40Thr), possibly contributing to partial adrenal insufficiency and sex reversal. The patient receives annual zoledronate, calcium, and vitamin D supplementation, with ongoing multidisciplinary follow-up. This represents the first reported coexistence of OI due to COL1A1 mutation with ambiguous genitalia in a 46,XY child, emphasizing the complexity of overlapping skeletal and gonadal phenotypes and the importance of longitudinal care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.